GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Other Current Payables

Regenicin (Regenicin) Other Current Payables : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin Other Current Payables?

Regenicin's Other Current Payables for the quarter that ended in Mar. 2023 was $0.00 Mil.


Regenicin Other Current Payables Historical Data

The historical data trend for Regenicin's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Other Current Payables Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Regenicin Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Regenicin Other Current Payables Related Terms

Thank you for viewing the detailed overview of Regenicin's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenicin (Regenicin) Business Description

Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines